IL316204A - Methods for administering myosin inhibitors - Google Patents

Methods for administering myosin inhibitors

Info

Publication number
IL316204A
IL316204A IL316204A IL31620424A IL316204A IL 316204 A IL316204 A IL 316204A IL 316204 A IL316204 A IL 316204A IL 31620424 A IL31620424 A IL 31620424A IL 316204 A IL316204 A IL 316204A
Authority
IL
Israel
Prior art keywords
administering
methods
myosin inhibitors
myosin
inhibitors
Prior art date
Application number
IL316204A
Other languages
English (en)
Hebrew (he)
Inventor
Vidya V Perera
Samira Merali
Amy Sehnert
Michael Cheung
Dewey Seto
Jeffrey Lockman
Marie-Laure Papi
Original Assignee
Myokardia Inc
Vidya V Perera
Samira Merali
Amy Sehnert
Michael Cheung
Dewey Seto
Jeffrey Lockman
Papi Marie Laure
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Myokardia Inc, Vidya V Perera, Samira Merali, Amy Sehnert, Michael Cheung, Dewey Seto, Jeffrey Lockman, Papi Marie Laure filed Critical Myokardia Inc
Publication of IL316204A publication Critical patent/IL316204A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B8/00—Diagnosis using ultrasonic, sonic or infrasonic waves
    • A61B8/06—Measuring blood flow
    • A61B8/065—Measuring blood flow to determine blood output from the heart
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H15/00—ICT specially adapted for medical reports, e.g. generation or transmission thereof
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
    • G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H70/00—ICT specially adapted for the handling or processing of medical references
    • G16H70/40—ICT specially adapted for the handling or processing of medical references relating to drugs, e.g. their side effects or intended usage

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medical Informatics (AREA)
  • Primary Health Care (AREA)
  • Hospice & Palliative Care (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Surgery (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL316204A 2022-04-26 2023-04-25 Methods for administering myosin inhibitors IL316204A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202263335028P 2022-04-26 2022-04-26
US202263335209P 2022-04-26 2022-04-26
US202263336254P 2022-04-28 2022-04-28
PCT/US2023/019710 WO2023211872A1 (en) 2022-04-26 2023-04-25 Methods of administering myosin inhibitors

Publications (1)

Publication Number Publication Date
IL316204A true IL316204A (en) 2024-12-01

Family

ID=86558746

Family Applications (1)

Application Number Title Priority Date Filing Date
IL316204A IL316204A (en) 2022-04-26 2023-04-25 Methods for administering myosin inhibitors

Country Status (12)

Country Link
US (4) US20230338378A1 (cg-RX-API-DMAC7.html)
EP (1) EP4514355A1 (cg-RX-API-DMAC7.html)
JP (1) JP2025515491A (cg-RX-API-DMAC7.html)
KR (1) KR20250016125A (cg-RX-API-DMAC7.html)
CN (2) CN119789856A (cg-RX-API-DMAC7.html)
AU (1) AU2023260472A1 (cg-RX-API-DMAC7.html)
CA (1) CA3249509A1 (cg-RX-API-DMAC7.html)
CL (1) CL2024003237A1 (cg-RX-API-DMAC7.html)
IL (1) IL316204A (cg-RX-API-DMAC7.html)
MX (1) MX2024013068A (cg-RX-API-DMAC7.html)
TW (1) TW202400570A (cg-RX-API-DMAC7.html)
WO (1) WO2023211872A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202006296YA (en) 2018-01-19 2020-08-28 Cytokinetics Inc Dihydrobenzofuran and inden analogs as cardiac sarcomere inhibitors
JP7438148B2 (ja) 2018-06-26 2024-02-26 サイトキネティックス, インコーポレイテッド 心臓サルコメア阻害剤
EP3814343B1 (en) 2018-06-26 2023-01-11 Cytokinetics, Inc. Cardiac sarcomere inhibitors
EP4370116B1 (en) 2021-07-16 2025-01-15 Cytokinetics, Inc. Aficamten dosage regimens for treating obstructive hypertrophic cardiomyopathy
WO2024182469A1 (en) * 2023-02-28 2024-09-06 MyoKardia, Inc. Myosin inhibitors for use in the treatment of hypertrophic cardiomyopathy

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9585885B2 (en) * 2012-12-10 2017-03-07 Kissei Pharmaceutical Co., Ltd. Substituted pyrido[2,3-g]quinazolines as dopamine D2 receptor agonists
SMT202000071T1 (it) * 2013-06-21 2020-03-13 Myokardia Inc Composti di pirimidinadione contro le condizioni cardiache
SG11202006296YA (en) 2018-01-19 2020-08-28 Cytokinetics Inc Dihydrobenzofuran and inden analogs as cardiac sarcomere inhibitors
JP7438148B2 (ja) 2018-06-26 2024-02-26 サイトキネティックス, インコーポレイテッド 心臓サルコメア阻害剤
EP3814343B1 (en) 2018-06-26 2023-01-11 Cytokinetics, Inc. Cardiac sarcomere inhibitors
MA53491A (fr) 2018-08-31 2021-09-15 Cytokinetics Inc Inhibiteurs de sarcomes cardiaques
CA3157629A1 (en) * 2019-11-10 2021-05-14 MyoKardia, Inc. Methods of treatment with myosin modulator
KR20230079053A (ko) * 2020-08-28 2023-06-05 미요카디아, 인크. 미오신 조절제를 이용한 치료 방법

Also Published As

Publication number Publication date
US20240115568A1 (en) 2024-04-11
CA3249509A1 (en) 2023-11-02
CL2024003237A1 (es) 2025-02-07
JP2025515491A (ja) 2025-05-15
US20250360132A1 (en) 2025-11-27
CN119789856A (zh) 2025-04-08
KR20250016125A (ko) 2025-02-03
WO2023211872A1 (en) 2023-11-02
AU2023260472A1 (en) 2024-10-24
EP4514355A1 (en) 2025-03-05
CN120549937A (zh) 2025-08-29
MX2024013068A (es) 2025-02-10
US20230338378A1 (en) 2023-10-26
US20250288586A1 (en) 2025-09-18
TW202400570A (zh) 2024-01-01

Similar Documents

Publication Publication Date Title
IL318748A (en) Compositions and methods for inhibiting KRAS
IL320739A (en) rock2 inhibitors
ZA202212146B (en) Inhibitors of nek7 kinase
PL4284511T3 (pl) Azachinoliny jako inhibitory cd38
IL321357A (en) KIF18A inhibitors and their uses
IL316616A (en) ROCK2 inhibitors
IL317768A (en) Methods for preparing tailored BTK inhibitors
SI4192813T1 (sl) Zaviralci transglutaminaz
PT4221709T (pt) Inibidores de imidazopiperazina das proteínas ativadoras da transcrição
SI4192814T1 (sl) Zaviralci transglutaminaz
IL307382A (en) Therapeutic inhibitors of GDF15 signaling
IL304123A (en) RNA transfer preparations and methods
IL326113A (en) Methods of using factor b inhibitors
LT4192812T (lt) Transgliutaminazės inhibitoriai
HK40123331A (en) Methods of administering myosin inhibitors
GB202107612D0 (en) Inhibitors of metallo-beta-lactamases
IL317760A (en) History of benzocarbazoles as DRP1 inhibitors
CA3293535A1 (en) Inhibitors of tyk2
CA3273897A1 (en) Inhibitors of tyk2
IL325331A (en) Tyk2 inhibitors, compositions containing them and their uses
PT4192812T (pt) Inibidores de transglutaminases
GB202107331D0 (en) Therapeutic inhibitors of GDF15 signalling
GB202104556D0 (en) Therapeutic inhibitors of GDF15 signalling
CA3294294A1 (en) Methods of using factor b inhibitors
CA3283726A1 (en) Methods of using factor b inhibitors